Grupo de Investigación Translacional de Tumores Sólidos Pediátricos

Área de Oncología

Heterogeneidad genómica en neuroblastoma (NB), especialmente en amplificación de MYCN.

Modelos de xenotrasplante de NB.

Importancia de la matriz extracelular y vascularización en NB.

Análisis morfológico y molecular de tumores esqueléticos infantiles neuroblásticos y malignos.

Coordinador
Dr. Samuel Navarro Fos
samuel.navarro@uv.es/navarro@uv.es  

Coordinador
Dra. Rosa Noguera Salvá
rosa.noguera@uv.es  

INVESTIGADORES
R4 Senior

Rosa Noguera Salvá    
Samuel Navarro Fos    

R3 Consolidado
R2 Novel / Emergente

Inmaculada Noguera Salvá
Mª Amparo López Carrasco
Sabina Sanegre Sans

R1 Predoctoral

Ezequiel Monferrer Garzarán
Isaac Vieco Martí

STAFF
Colaborador/a
Enfermero/a
Técnico/a
Apoyo
Publicaciones
Does PAX7 and NKX2.2 immunoreactivity in Ewing sarcoma have prognostic significance?. Machado I, Charville GW, Yoshida A, Navarro S, Righi A, Gambarotti M, Scotlandi K, Lopez-Guerrero JA, Llombart-Bosch A. Virchows Archiv. 2022 Jan 5. doi: 10.1007/s00428-021-03254-8. PMID: 34985580

A G316A polymorphism in the ornithine decarboxylase gene promoter modulates mycn-driven childhood neuroblastoma. Gamble L, Purgato S, Henderson M, Di Giacomo S, Russell A, Pigini P, Murray J, Valli E, Milazzo G, Giorgi F, Cowley M, Ashton L, Bhalshankar J, Schleiermacher G, Rihani A, Van Maerken T, Vandesompele J, Speleman F, Versteeg R, Koster J, Eggert A, Noguera R, Stallings R, Tonini G, Fong K, Vaksman Z, Diskin S, Maris J, London W, Marshall G, Ziegler D, Hogarty M, Perini G, Norris M, Haber M. Cancers. 2021 Apr 9;13(8):1807. doi: 10.3390/cancers13081807. PMID: 33918978

Characterizing the invasive tumor front of aggressive uterine adenocarcinoma and leiomyosarcoma. Sanegre S, Eritja N, de Andrea C, Diaz-Martin J, Diaz-Lagares A, Jacome MA, Salguero-Aranda C, Garcia Ros D, Davidson B, Lopez R, Melero I, Navarro S, Ramon y Cajal S, de Alava E, Matias-Guiu X, Noguera R. Frontiers in Cell and Developmental Biology. 2021 Jun 3;9:670185. doi: 10.3389/fcell.2021.670185. PMID: 34150764

Frequency and prognostic impact of alk amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Bellini A, Potschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts DR, Bhalshankar J, Bown N, de Preter K, Clement N, Combaret V, Font de Mora J, George SL, Jimenez I, Jeison M, Marques B, Martinsson T, Mazzocco K, Morini M, Muhlethaler-Mottet A, Noguera R, Pierron G, Rossing M, Taschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz W, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, Tweddle DA, Ladenstein R, Schleiermacher G. Journal of Clinical Oncology. 2021 Oct 20;39(30):3377-3390. doi: 10.1200/JCO.21.00086. PMID: 34115544

Immunometabolism modulation in therapy. Monferrer E, Sanegre S, Vieco-Marti I, Lopez-Carrasco A, Farinas F, Villatoro A, Abanades S, Manes S, de la Cruz-merino L, Noguera R, Naranjo T. Biomedicines. 2021 Jul 9;9(7):798. doi: 10.3390/biomedicines9070798. PMID: 34356862

Integrated CGH/WES analyses advance understanding of aggressive neuroblastoma evolution: a case study. Corallo D, Zanon C, Pantile M, Tonini G, Zin A, Francescato S, Rossi B, Trevisson E, Pinato C, Monferrer E, Noguera R, Alino S, Herrero M, Biffi A, Viscardi E, Aveic S. Cells. 2021 Oct 9;10(10):2695. doi: 10.3390/cells10102695. PMID: 34685674

Intra-tumour genetic heterogeneity and prognosis in high-risk neuroblastoma. Lopez-Carrasco A, Berbegall A, Martin-Vano S, Blanquer-Maceiras M, Castel V, Navarro S, Noguera R. Cancers. 2021 Oct 15;13(20):5173. doi: 10.3390/cancers13205173. PMID: 34680323

Metabolic classification and intervention opportunities for tumor energy dysfunction. Monferrer E, Vieco-Marti I, Lopez-Carrasco A, Farinas F, Abanades S, de la Cruz-Merino L, Noguera R, Alvaro Naranjo T. Metabolites. 2021 Apr 23;11(5):264. doi: 10.3390/metabo11050264. PMID: 33922558

Neuroendocrine differentiation in a large series of genetically-confirmed Ewing’s sarcoma family tumor: Does it provide any diagnostic or prognostic information?. Machado I, Navarro S, Lopez-Guerrero J, Verdini L, Picci P, Giner F, Llombart-Bosch A. Pathology, Research and Practice. 2021 Feb 6;219:153362. doi: 10.1016/j.prp.2021.153362. PMID: 33610950

Solitary fibrous tumor: integration of clinical, morphologic, immunohistochemical and molecular findings in risk stratification and classification may better predict patient outcome. Machado I, Nieto Morales MG, Cruz J, Lavernia J, Giner F, Navarro S, Ferrandez A, Llombart-Bosch A. International Journal of Molecular Sciences. 2021 Aug 30;22(17):9423. doi: 10.3390/ijms22179423. PMID: 34502329

SuperHistopath: a deep learning pipeline for mapping tumor heterogeneity on low-resolution whole-slide digital histopathology images. Zormpas Petridis K, Noguera R, Ivankovic D, Kolarevic R, Jamin Y, Yuan Y. Frontiers in Oncology. 2021 Jan 20;10:586292. doi: 10.3389/fonc.2020.586292. PMID: 33552964

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. Masanas M, Masia N, Suarez-Cabrera L, Olivan M, Soriano A, Majem B, Devis-Jauregui L, Burgos-Panadero R, Jimenez C, Rodriguez-Sodupe P, Boloix A, Toledano I, Guillen G, Navarro A, Llobet-Navas D, Villanueva A, Sanchez de Toledo J, Roma J, Noguera R, Moreno L, Krauss R, Gallego S, Santamaria A, Segura M. Clinical and Translational Medicine. 2021 Oct;11(10):e533. doi: 10.1002/ctm2.533. PMID: 34709738

Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma. Burgos-Panadero R, El Moukhtari SH, Noguera I, Rodriguez-Nogales C, Martin-Vano S, Vicente-Munuera P, Canete A, Navarro S, Blanco-Prieto MJ, Noguera R. International Journal of Pharmaceutics. 2021 Aug 28;608:121058. doi: 10.1016/j.ijpharm.2021.121058. PMID: 34461172

11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. Siaw J, Javanmardi N, Van den Eynden J, Lind D, Fransson S, Martinez-Monleon A, Djos A, Sjoberg R, Ostensson M, Caren H, Troen G, Beiske K, Berbegall Beltrán A, Noguera Salva R, Lai W, Kogner P, Palmer R, Hallberg B, Martinsson T. Cell Reports. 2020 Sep 22;32(12):108171. doi: 10.1016/j.celrep.2020.108171. PMID: 32966799

A three-dimensional bioprinted model to evaluate the effect of stiffness on neuroblastoma cell cluster dynamics and behavior. Monferrer Garzarán E, Martín Vañó S, Carretero Martínez A, Garcia-Lizarribar A, Burgos Panadero R, Navarro Fos S, Samitier J, Noguera Salva R. Scientific Reports. 2020 Apr 14;10(1):6370. doi: 10.1038/s41598-020-62986-w. PMID: 32286364

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Ambros I, Tonini G, Potschger U, Gross N, Mosseri V, Beiske K, Berbegall A, Benard J, Bown N, Caron H, Combaret V, Couturier J, Defferrari R, Delattre O, Jeison M, Kogner P, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Valent A, Van Roy N, Villamon E, Janousek D, Pribill I, Glogova E, Attiyeh E, Hogarty M, Monclair T, Holmes K, Valteau-Couanet D, Castel V, Tweddle D, Park J, Cohn S, Ladenstein R, Beck-Popovic M, De Bernardi B, Michon J, Pearson A, Ambros P. Journal of Clinical Oncology. 2020 Nov 1;38(31):3685-3697. doi: 10.1200/JCO.18.02132. PMID: 32903140

Controversial issues in soft tissue solitary fibrous tumors: A pathological and molecular review. Machado I, Nieto-Morales G, Cruz J, Navarro Fos S, Giner F, Ferrandez Izquierdo A, Lopez-Soto M, Lavernia J, Llombart-Bosch A. Pathology International. 2020 Mar;70(3):129-139. doi: 10.1111/pin.12894. PMID: 31904167

Digital Image Analysis Applied to Tumor Cell Proliferation, Aggressiveness, and Migration-Related Protein Synthesis in Neuroblastoma 3D Models. Monferrer Garzarán E, Sanegre Sans S, Martín Vañó S, Garcia-Lizarribar A, Burgos Panadero R, Lopez Carrasco M, Navarro Fos S, Samitier J, Noguera Salva R. International Journal of Molecular Sciences. 2020 Nov 17;21(22):8676. doi: 10.3390/ijms21228676. PMID: 33212997

Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes. Fernandez Blanco B, Berbegall A, Martín Vañó S, Castel V, Navarro Fos S, Noguera Salva R. Neoplasia. 2020 Nov 12;23(1):12-20. doi: 10.1016/j.neo.2020.11.001. PMID: 33190090

Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line. López-Carrasco A, Martín-Vañó S, Burgos-Panadero R, Monferrer E, Berbegall AP, Fernández-Blanco B, Navarro S, Noguera R. Journal of Experimental & Clinical Cancer Research. 2020 Oct 28;39(1):226. doi: 10.1186/s13046-020-01729-1. PMID: 33109237

Integrating the Tumor Microenvironment into Cancer Therapy. Sanegre Sans S, Lucantoni F, Burgos Panadero R, De La Cruz-Merino L, Noguera Salva R, Alvaro Naranjo T. Cancers. 2020 Jun 24;12(6):1677. doi: 10.3390/cancers12061677. PMID: 32599891

Potential Molecular Players of the Tumor Microenvironment in Extracranial Pediatric Solid Tumors. Noguera R, Alvaro Naranjo. Cancers. 2020 Oct 9;12(10):2905. doi: 10.3390/cancers12102905. PMID: 33050312

Publisher Correction: Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages. Juan Ribelles A, Barberá S, Yáñez Y, Gargallo P, Segura V, Juan B, Noguera Salva R, Piqueras M, Fornés-Ferrer V, Font de Mora J, Cañete A, Castel V. Scientific Reports. 2020 Jan 31;10(1):1914. doi: 10.1038/s41598-020-58428-2. PMID: 32005943

Solitary fibrous tumor: a case series identifying pathological adverse factors-implications for risk stratification and classification (pg 1, 2019). Machado I, Morales G, Cruz J, Lavernia J, Giner F, Navarro Fos S, Ferrandez Izquierdo A, Llombart-Bosch A. Virchows Archiv. 2020 Apr;476(4):625-626. doi: 10.1007/s00428-019-02697-4. PMID: 31655865

Solitary fibrous tumor: a case series identifying pathological adverse factors-implications for risk stratification and classification. Machado I, Nieto Morales G, Cruz J, Lavernia J, Giner F, Navarro Fos S, Ferrandez Izquierdo A, Llombart-Bosch A. Virchows Archiv. 2020 Apr;476(4):597-607. doi: 10.1007/s00428-019-02660-3. PMID: 31529158

The topology of vitronectin: A complementary feature for neuroblastoma risk classification based on computer-aided detection. Vicente-Munuera P, Burgos Panadero R, Noguera I, Navarro Fos S, Noguera Salva R, Escudero L. International Journal of Cancer. 2020 Jan 15;146(2):553-565. doi: 10.1002/ijc.32495. PMID: 31173338

Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Garcia-Alfonso P, Garcia-Carbonero R, Garcia-Foncillas J, Perez-Segura P, Salazar R, Vera R, Ramon Y Cajal S, Hernandez-Losa J, Landolfi S, Musulen E, Cuatrecasas M, Navarro Fos S. Clinical & Translational Oncology. 2020 Nov;22(11):1976-1991. doi: 10.1007/s12094-020-02357-z. PMID: 32418154

Proyectos
Referencia: PI20/01107
Título: Neuroblastoma: estrategias mecanoterapéuticas basadas en modelos 3D y tumores derivados de pacientes con microambiente rico en vitronectina
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Rosa Noguera Salvá
Duración: 2021 – 2023
Presupuesto: 232.320 €

Referencia: 12/2019-P2Y01D
Título: Espacio intercelular: Bioimagen microscópica, Fase II
Entidad Financiadora: Fundación Neuroblastoma
Investigador principal: Rosa Noguera Salvá
Duración: 2019 – 2021
Presupuesto: 90.000 €

Referencia: PI17/01558
Título: Identificación y validación de nuevas terapias, modelos preclínicos y marcadores de respuesta
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Rosa Noguera Salvá
Duración: 2018 – 2020
Presupuesto: 123.420 €

Referencia: CB16/12/00484
Título: CIBER Oncología (CIBERONC)
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Rosa Noguera Salvá
Duración: 2017 –
Presupuesto: 250.000 €

+ Información
Título: Búsqueda de dianas terapéuticas en los puntos de contacto de la célula tumoral con su matriz extracelular en tumores neuroblásticos
Doctorando: Burgos Panadero, Rebeca
Director: Noguera Salvá, Rosa; Navarro Fos, Samuel
Fecha: 31/07/2020
Universidad: Universitat de València